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Antiphospholipid syndrome is associated with an increased risk of thrombosis and pregnancy loss. Annexin
A5 (Anxa5) is a candidate autoantigen. It is not known, however, whether endogenousAnxa5 prevents foetal
loss during normal pregnancy.We found significant reductions in litter size and foetal weight in Anxa5-null
mice (Anxa5-KO). These changes occurred even when only the mother was Anxa5-KO. A small amount of
placental fibrin deposition was observed in the decidual tissues, but did not noticeably differ between
wild-type andAnxa5-KOmice.However, immunoreactivity for integrin beta 3/CD61, a plateletmarker, was
demonstrated within thrombi in the arterial canals only in Anxa5-KO mothers. Subcutaneous
administration of the anticoagulant heparin to pregnant Anxa5-KO mice significantly reduced pregnancy
loss, suggesting that maternal Anxa5 is crucial for maintaining intact placental circulation. Hence, the
presence of maternal Anxa5 minimises the risk of thrombosis in the placental circulation and reduces the
risk of foetal loss.
P
regnancy loss is not a rare complication in human pregnancy. Anti-phospholipid syndrome is thought to be
a major cause of early pregnancy loss1. This condition is characterised by the presence of anti-phospholipid
antibody. In fact, auto-antibodies to various phospholipids and phospholipid binding proteins have been
reported2. Anxa5 has been proposed to be a common auto-antigen in anti-phospholipid syndrome3.
Anxa5 is amember of the annexin family of proteins, which consists of 12 structurally related, highly conserved
proteins in humans and mice4. Anxa5 was originally discovered as a candidate anticoagulant protein in the
placenta5,6, but its involvement in the prevention of inappropriate coagulation in the placenta has not been
elucidated. In the human and mouse placenta, Anxa5 is extensively distributed on the cell surface of syncytio-
trophoblasts7–9. Patients with antiphospholipid syndrome and lupus erythematosus often exhibit autoantibodies
against Anxa5, and pregnant patients sometimes show spontaneous foetal loss during the early stages of preg-
nancy10–12. However, there has been no direct in vivo evidence that endogenous Anxa5, when expressed by either
the mother or the foetus, prevents foetal loss during pregnancy.
The annexins are characterised by their related structures, which are composed of four repeats (eight for
annexin A6) of approximately 60 amino acids13 that allow calcium-dependent binding to phospholipid mem-
branes. Anxa5 has been shown to be involved in multiple cellular processes, such as intracellular signalling,
mineralisation of cartilage and inhibition of phospholipase A2 and protein kinase C14–18. Anxa5 is well known for
its capacity to detect early apoptotic cells due to its high affinity for exposed phosphatidylserine on the surfaces of
these cells19. Therefore, it has been proposed that the binding of Anxa5 to cell surface-exposed phosphatidylserine
on vascular endothelial cells in the placenta is crucial for suppressing inappropriate blood coagulation during
pregnancy3,11,20. Binding of autoantibodies to Anxa5 can disrupt the protective shield in patients with antipho-
spholipid syndrome, causing placental thrombosis and, ultimately, pregnancy loss3,8,11,21. Although, in support of
this view, intravenous administration of antibodies against Anxa5 to pregnant mice has been shown to lead to
placental thrombosis and foetal loss8, it is not clear whether this is a nonspecific reaction to acutely formed
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We established anAnxa5-null mousemodel (Anxa5-KO), and our
initial studies showed that the strain was viable and fertile and lacked
an obviously altered phenotype22. In the present study, we dem-
onstrate that the number of foetuses, and hence the litter size, were
significantly reduced by deficient maternal Anxa5 production. This
result reveals that the maternal supply of Anxa5 to the circulation is
necessary for maintaining a fully intact pregnancy.
Results
The litter sizes of Anxa5-KO derived from Anxa5-KO x Anxa5-KO
crosses were significantly smaller than the sizes of litters from
C57BL/6J (WT) x WT crosses (Fig. 1-a, Anxa5-KO: 6.30 6
0.35 vs. WT: 8.33 6 0.30, n530, p,0.001). When the number of
ovulated ova on themorning of oestrus was counted by dissecting the
oviduct and examining the ova in the ampulla, no difference was
found in the number of ova in the Anxa5-KO andWTmice (Anxa5-
KO: 8.28 6 0.42 vs. WT: 8.86 6 0.80, n57). Therefore, some
embryos were lost during pregnancy in the Anxa5-KO mice. By
analysing the progression of pregnancy, a clear reduction in the
average litter size was observed between days 12 and 18. There was
no difference between the number of embryos on day 18 and the
newborn litter size (Fig. 1-a). Foetal loss in the Anxa5-KO was con-
sistently observed regardless of parity (parity n51 to 3, data not
shown).
Smaller foetuses were found in the uteruses of Anxa5-KOmice on
days 12, 15 and 18 of pregnancy (Fig. 1-b). Foetuses of WT and
Anxa5-KO mice were compared on pregnancy day 15 (Fig. 1-c, d).
Both the number (WT: 9.6 6 0.24, n55 vs. Anxa5-KO: 6.5 6 0.48,
n57) andweight (Fig. 1-d) of the foetuses were smaller in Anxa5-KO
mice (Supplemental table 1). In addition to living, intact foetuses, the
existence of remnants of the conceptus in six of seven pregnant
Anxa5-KO mice was observed on day 15 of pregnancy
(Supplemental table 1).
There was no difference in the plasma levels of progesterone on
days 12 and 18 of pregnancy between the Anxa5-KO and WT mice
(day 12: 115.9 6 16.5 vs. 126.7 6 19.7 ng/ml, respectively, n55,
p.0.05; day 18: 107.4 6 25.3 vs. 68.5 6 11.5 ng/ml, respectively,
n55, p.0.05). In addition, the lengths of pregnancy (Anxa5-KO:
20.5 6 0.5, n56 vs. WT: 21 6 0.8 days, n5 8) and the oestrous cycle
(Anxa5-KO: 5.2 6 0.2, n516 vs. WT: 5.2 6 0.2 days, n525) showed
no significant differences (p.0.05 respectively).
The placentae on day 15 of pregnancy showed fewer erythrocytes
in both the labyrinth and junctional zones of Anxa5-KOmice (Fig. 2-
a, b). There were many foetal erythrocytes (large eosinophylic cells
with nucleus) but fewer maternal erythrocytes (small and without
nucleus) in Anxa5-KO placenta (Fig. 2c, d). It was revealed that only
nucleated foetal erythrocytes were present in the tissue of absorbed
conceptuses (Fig. 2-e). Large pink homogeneous structures, which
were likely thrombi, were observed both in the labyrinth and junc-
tional zone of the placentae of smaller foetuses on day 18 (Fig. 2-f).
Immunohistochemistry with anti-integrin beta 3/CD61, a platelet
marker, clearly showed thrombi in the placentae of Anxa5-KO mice
(Fig. 3). No such thrombus was observed in the WT placentae.
Thrombi were observed in all placentae of healthy conceptuses in
the Anxa5-KO mice (ten placentae from three mice). Thrombi were
observed beneath the trophoblast giant cell layer. Alternatively, fibrin
deposition detected with immunohistochemistry for fibrinogen/
fibrin interactions were mainly in the decidual layer, outside the
trophoblast giant cell layer, of WT and Anxa5-KO mice (Supple-
mental figure 1). The intensity of fibrin immunoreactivity was not
different between the WT and Anxa5-KO mice.
Cross-breeding experiments of Anxa5-KO and WT mice showed
that only litters bred using Anxa5-KO females (f) showed a reduced
number of pups (Fig. 4-a). Crossing Anxa5-KO females (f) with
Anxa5-KOmales (m) or withWT (m) resulted in the same reduction
in litter size (Fig. 4-a). Immunohistochemistry with the placentae
Figure 1 | The deficiency of maternal Anxa5 affects embryonic growth
and litter size. a: Number of ovulated ova, embryos and litter size in
Anxa5-KO (AX52/2) mice. The number of ova in the oviduct was counted
on the morning of oestrus for Anxa5-KO and C57BL/6J (WT) mice. The
number of embryos was counted on each pregnancy day (12, 15 and 18).
The litter size was counted on the day of delivery. The values are expressed
as the mean and the standard error of the mean. Asterisks reveal a
significant difference (Bonferroni method p,0.05). b: The conceptuses
were observed on pregnancy days 9, 12, 15 and 18 of WT and Anxa5-KO
mice. The arrows indicate smaller foetuses. (Scale bar 5 1 cm). c: A
representative picture of an embryo and placenta on pregnancy day 15
corresponding to samples WT #3 and Anxa5-KO #2 in supplemental table
1. d: The weight of the embryos on pregnancy day 15. Foetal weight was
measured on pregnancy day 15 (n548 for WT, n546 for Anxa5-KO,
individual data are presented in supplemental table 1).
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collected from four different combinations of parents in the cross-
breeding experiments on pregnancy day 15 clearly showed that the
‘‘wire loop’’ pattern of Anxa5-coated syncytiotrophoblast surfaces
and vessel walls was lost in Anxa5-KO mothers (Fig. 4-b, Anxa5-
KO (f)).
Blood taken from Anxa5-KO mice coagulated faster than that
from WT mice, demonstrating lower levels of anticoagulant activity
in Anxa5-KO mice (Fig. 5-a). Finally, we found that the administra-
tion of heparin (100 IU/day on pregnancy days 12, 14 and 16) to
Anxa5-KO mothers significantly increased the litter size (Fig. 5-b).
Discussion
The results of the present study clearly demonstrate that the defi-
ciency of Anxa5 results in significant foetal loss. As smaller foetuses
were found in the uteruses of Anxa5-KO mothers, embryos were
restricted in growth. Severely growth-restricted foetuses may have
died later and been absorbed, resulting in the reduction of litter size
in Anxa5-KO mice. The inappropriate formation of thrombi in the
placental circulation is linked to foetal growth retardation and
absorption. These features of pregnant Anxa5-KO mice are similar
to complications of infertility caused by anti-phospholipid syn-
drome1–3,23,24.
Anxa5 has been postulated to be a significant auto-antigen for
pregnancy loss3,21,25. The present results provide direct evidence that
maternal Anxa5 acts as an anti-thrombotic agent during pregnancy.
Foetuses are lost only whenmaternal Anxa5 is absent. Therefore, the
absence of Anxa5, or possibly mutations affecting its binding capa-
city to phospholipids, can explain the molecular mechanism of preg-
nancy loss in patients suffering from antiphospholipid syndrome
and lupus erythematosus3,26,27. The placentae of Anxa5-KO were
always anaemic, and thrombi were also found even healthy placen-
tae. These changes were thought to cause smaller embryos and
increase the likelihood of foetal death. Fibrin deposition was mainly
observed in the decidual tissues of bothWT andAnxa5-KOmice, but
thrombi were detected in the placentae only of Anxa5-KO placenta.
This finding indicates that platelet activation is primarily induced
under Anxa5-defiencnt conditions not depending on the quantity of
fibrin deposition. As some other annexins were also shown to have
an affinity for phosphatidyl serine28, it is possible that they would
compensate somewhat the deficiency of Anxa5.Our data suggest that
Anxa5 could play a role in the prevention of inappropriate platelet
activation. Placental Anxa5 is necessary for reducing the possibility
of inappropriate thrombosis and for a fully intact pregnancy.
Additionally, there was no difference in the plasma levels of pro-
gesterone, the length of pregnancy or the length of the oestrous cycle,
indicating the intact reproductive function of Anxa5-KO mice with
the exception of their tendency to form thrombi in their placentae.
Cross-breeding experiments of Anxa5-KO and WT mice showed
that the presence of maternal Anxa5 is crucial for themaintenance of
pregnancy. Only litters bred using Anxa5-KO (f) showed a reduced
number of pups. Hence, heterozygous embryos delivered from
Anxa5-KO mice did not rescue the phenotype. Anxa5 was shown
to be bound to the surface of the syncytiotrophoblasts of placental
vessels, potentially shielding the phosphatidylserine signal on the
outer cell surface7. Immunohistochemistry of the placentae showed
that the Anxa5-coating of the walls was lost in Anxa5-KO mothers.
These data clearly indicate that Anxa5 is supplied maternally,
although the placenta is entirely of foetal origin29. Furthermore,
blood from Anxa5-KO mice showed lower levels of anticoagulant
activity. This observation, in concert with the finding that the forma-
Figure 3 | Immunohistochemistry of a placenta using anti-integrin beta-
3A/CD61. The placentas were collected on pregnancy day 15 and
subjected to immunohistochemistry with an antibody to integrin beta-3A/
CD61 platelet marker. The red arrowheads indicate positive reactions.
Figure 2 | Histological analysis of the placenta. The placentas were
collected on pregnancy days 15 and 18. They were stained with
hematoxylin-eosin. a, b: lower magnification. c, d: higher magnification of
labyrinth zone. e: Conceptus tissue being absorbed. f: The placenta of a
growth-retarded foetus collected on pregnancy day 18. The yellow and
green arrows indicate the labyrinth zone and the junctional zone,
respectively. The black and white arrows indicate homogeneous undefined
extracellular matrix material in each placenta.
www.nature.com/scientificreports
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tion of thrombi in the arterial circuitry did not follow fibrin depos-
ition, suggests that it is also important for platelets to be shielded with
Anxa530. Finally, we found that the administration of heparin to
Anxa5-KO mothers significantly increased litter size. Heparin inhi-
bits thrombin and thrombin activates platelets31. So, the administra-
tion of Anxa5 is thought to inhibit platelet thrombi formation. These
data clearly demonstrate that foetal loss in Anxa5-KOmice is caused
by inappropriate thrombogenesis.
The mouse placenta is hemochorial, and structures functionally
equivalent to villi in the human placenta are directly bathed in the
mother’s blood, as in humans29,32. Thus, the present results obtained
from this Anxa5-deficient mouse model could be extrapolated to
understand the pathogenesis of preeclampsia and infertility caused
by antiphospholipid syndrome in humans.
Methods
Animals. The Anxa5-KO line was first established with a mixed 129Sv/C57BL/6
background and then backcrossed to the C57BL/6 background for more than 10
generations22. Wild-type C57BL/6J mice (WT) were obtained from CLEA Japan, Inc.
(Tokyo, Japan) for control experiments. The mice bred in our laboratory were
maintained at 23 6 3uC with a controlled light cycle of 14L:10D (light on 5:00–19:00
h). Food and tap water were supplied ad libitum. All experiments were performed
according to the guidelines for animal experiments of Kitasato University, and the
experimental plans were approved by the Committee for Laboratory Animals, Care
and Use of the School of Veterinary Medicine, Kitasato University.
Vaginal smears were taken daily, and pregnancy was induced by placing a female
into a male’s cage on the evening of pro-oestrous. The presence of a vaginal plug was
confirmed the next morning, and the day of oestrous was designated as day 0 of
pregnancy. The pups were counted on themorning of delivery. To count the ovulated
ova, eachmousewas lightly anesthetised with diethyl ether (Kanto Chemical Co., Inc.,
Tokyo, Japan) and sacrificed using cervical dislocation on themorning of oestrus. The
oviduct was dissected, and the number of ova in the oviduct was counted. Pregnant
animals were also sacrificed on pregnancy days 12, 15 and 18 to count the foetuses in
the uteruses of Anxa5-KO and WT mice.
Tissue preparation for histological analysis.The placentas were collected frommice
in various experimental groups and fixed in 4% paraformaldehyde overnight at 4uC.
The tissue blocks were washed, dehydrated and embedded in paraffin. Four-micron
sections were made and dried in an incubator at 37uC overnight. The dried sections
were stained with hematoxylin-eosin or subjected to immunohistochemistry for
Anxa5, CD61 and fibrin. The hematoxylin and eosin solutions were obtained from
Muto Pure Chemicals Co., LTD. (Tokyo, Japan).
Immunohistochemistry. After hydration, the sections were incubated with 5%
normal rabbit serum for 1 hour to reduce non-specific antibody binding. The
primary antibody was anti-Anxa5 rabbit serum raised in our laboratory33. Anti-
integrin beta-3A/CD61 [EPR2417Y] monoclonal rabbit IgG from GeneTex
Figure 5 | The deficiency of maternal Anxa5 affects blood coagulation. a:
The blood clotting time of Anxa5-KO. Blood (500 ml) was obtained by
heart puncture and warmed at 37uC. The clotting time was measured by
shaking the tube every 30 seconds. The values are expressed as the mean
and the standard error of the mean. The Mann-Whitney’s U-test was
performed. b: The effect of heparin on the litter size of Anxa5-KO mice.
The Anxa5-KO mice were subcutaneously administered saline or heparin
(100 IU) on pregnancy days 12, 14 and 16. The Student’s t-test was
performed (*p,0.05).
Figure 4 | Cross-breeding of Anxa5-KO and WT. a: Changes in the litter
size after cross breeding of Anxa5-KOmice andWTmice. WT and Anxa5-
KO (AX52/2) were mated in different combinations. Asterisks denote
significant differences (Bonferroni test p,0.05). b: Immunohistochemical
distribution of Anxa5 in the placentae of mice on pregnancy day 15. WT
and Anxa5-KO were mated in different combinations. WT (f): the mother
was WT. WT (m): the father was WT. Anxa5-KO (f): the mother was
Anxa5-KO. Anxa5-KO (m): the father was Anxa5-KO. The arrows indicate
that there was no Anxa5 on the surface of the syncytiotrophoblasts in the
labyrinth zone (black) or the walls of the arterial canal of the junctional
zone (white) of the placenta from the combination of Anxa5-KO (f) and
WT (m).
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SCIENTIFIC REPORTS | 2 : 827 | DOI: 10.1038/srep00827 4
(Funakoshi, Tokyo, Japan) and anti-fibrinogen gamma (G-20) goat serum (Santa
Cruz Biotechnology, Santa Cruz, CA, U.S.A.) were also used. These antibodies were
used at a dilution of 1:100 and 1:1,000, respectively. The antiserum for Anxa5 was
diluted to 1:10,000, and the sections were incubated with the serum overnight at 4uC.
The second antibody system for visualisation was the ImmPRESS reagent anti-rabbit,
anti-mouse or anti-goat IgG POD (Vector Laboratories, Burlingame, CA, U.S.A.).
The specimens were counterstained with hematoxylin.
Measurement of blood clotting time.Themice were lightly anesthetisedwith diethyl
ether. The blood samples (500 ml) were then obtained by cardiopuncture and placed
immediately into plastic test tubes. The tubes were incubated at 37uC and shaken
gently every 30 seconds to confirm coagulation. The time needed for complete
coagulation was measured.
Administration of heparin.Heparin was obtained fromAjinomoto Co., Inc. (Tokyo,
Japan). Heparin (100 IU/0.1 ml) was given subcutaneously in the backs of Anxa5-KO
mice every other day from pregnancy day 12 to 18.
Time-resolved fluorometric assay of progesterone.The progesterone concentration
was determined with a time-resolved fluorometric immunoassay using the Delfia
system (Perkin Elmer Life Sciences, Tokyo, Japan). Anti-progesterone raised in our
laboratory was labelled with Europium using the Delfia Eu-labeling kit (Perkin Elmer
Life Sciences). An immunoplate (96 wells, Nunc Co., Roskilde, Denmark) was coated
with 100 ml/well of progesterone-BSA (2.5 mg/ml, Steraloids Inc., Newport, RI) and
blockedwith 200 ml/well of a blocking buffer (50 mMNa2HPO4, 0.1% BSA). Then, an
optimally diluted sample (100 ml/well) and Eu-labelled antibody (100 ml/well) were
incubated for 2 hours at room temperature, and the intensity of the bound label was
measured using the Delfia Plate Fluorometer. All samples were run in duplicate.
Statistics. Each value represents the mean 6 standard error of the mean. Statistical
analysis was performed using the Student’s t-test for the comparison of two groups
and the Bonferroni test for the multiple comparison. The Mann-Whitney U-test was
used for discontinuous values obtained in the blood clotting test. P values less than
0.05 were considered statistically significant.
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